This paper describes the interactions among Medicaid Best Price rebate calculations and those for 340B Ceiling Prices and Average Sales Prices which can create disincentives for providers and therapy developers … Read More
Orphan cell and gene therapies more likely to reach approval than larger drug pipeline: study
Our new report shows that cell and gene therapies for orphan diseases and hematological cancers are two to 3.5 times more likely to be successful than other types of treatments … Read More
Are Cell and Gene Therapy programs a better bet?
Compared to traditional drug development programs, do durable cell and gene therapy (CGT) programs experience higher or lower clinical success rates? Estimating the Probability of Technical and Regulatory Success (PTRS) … Read More
New Analysis by Tufts’ NEWDIGS Shows that Durable Cell and Gene Therapies Have Substantially Higher Clinical Success Rates than Other Treatments
Findings to be shared during ARM’s annual Cell & Gene Meeting on the Mesa Carlsbad, CA – The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization championing the benefits … Read More
Extending the vision of adaptive point-of-care platform trials to improve targeted use of drug therapy regimens: An agile approach in the learning healthcare system toolkit
Publication in Contemporary Clinical Trials To improve drug regimen use, we propose an adaptive point-of-care (APoC) platform trial for robust real-world evidence (RWE) production, addressing uncertainties post-market. Using rheumatoid arthritis … Read More
Innovating methods for planning, producing, and using real-world evidence
Real-world data (RWD) are a critical element of the evidence needed to help reach this goal, potentially informing a new drug’s development or providing insight for its use after it … Read More
Payer and developer perspectives on alternative payment models
Expert Review of Pharmacoeconomics & Outcomes Research, Volume 24, 2024 – Issue 2Moradian, R., Meshesha, T., Trusheim, M., & Barlow, J. F. The paper reports the results of a survey … Read More
ISPOR 2023 Workshop Recap: “From Concept to Practice: How to Tactically Design a Feasible Outcomes-Based Contract in Oncology”
Across health care in the United States, stakeholders are increasingly looking for ways to reward value, especially when it comes to improving health outcomes. That’s why, earlier this month, an … Read More
Symposium recap: Uncertainty Management in Drug Evaluations: From Evidence to Reimbursement & Clinical Use
On Friday, May 5th, NEWDIGS at Tufts Medical Center co-hosted a research symposium with fellow researchers and long-time collaborators from Utrecht University and Harvard Medical School (HMS). The event, titled Uncertainty … Read More
How an RWE Value-Based Infrastructure Could Enable Payment Innovation
Tuesday, June 13, 2023 The Center for Biomedical System Design’s (CBSD) NEWDIGS at Tufts Medical Center and the Innovative Medicines Initiative’s Health Outcomes Observatory (H2O) are pleased to announce that we will … Read More